UK Markets closed

Tiziana Life Sciences PLC (TIZAF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.0000+0.1500 (+17.65%)
At close: 11:53AM EDT
Sign in to post a message.
  • a
    achin
    I heard about TLSA the other day on (http://Stocks-tracker.com). It’s looking like an interesting play.
  • C
    Catherine Wood worm
    I can't believe it Tesla $tsla is down this much.
  • E
    Enw_Investor
    More good news for TLSA.

    Precision Bio inks licensing deal with Tiziana Life for foralumab in cancer. This is an exclusive license agreement to explore Tiziana’s foralumab as an agent to induce tolerance of allogeneic CAR T cells to improve the clinical outcome of CAR T cell therapy.

    Precision will be responsible for the development, commercialization, and costs for use of foralumab, and Tiziana will receive upfront payment, certain milestone payments, and royalties for foralumab.

    https://www.tizianalifesciences.com/news-item?s=2021-09-02-precision-biosciences-and-tiziana-life-sciences-announce-exclusive-license-agreement-to-evaluate-foralumab-a-novel-fully-human-anti-cd3-monoclonal-antibody-in-conjunction-with-allogeneic-car-t-candidates-for-cancer-treatment
    Tiziana Life Sciences
    www.tizianalifesciences.com
  • A
    Adrián
    Buy Today
  • E
    Enw_Investor
    Good news today! Study results from TLSA of intranasally administered foralumab published in the peer-reviewed "Frontiers in Immunology" journal.

    The aim of the study was to assess safety of intranasal Foralumab and evaluate its potential benefits in treating immune hyperactivity and lung inflammation in mild to moderate COVID-19 patients in Brazil.

    Foralumab was well-tolerated, and no serious adverse events were observed.
    Treatment with Foralumab resulted in significant reduction in lung inflammation.
    The CT scan data of patients receiving Foralumab compared to control cohort strongly correlated with significant reduction in levels of inflammatory markers, such as IL-6 levels (69%; p=0.031) and CRP (85%; p=0.032) at day 10.

    Tiziana will be shortly initiating a Phase 2 Proof-of-concept study in Brazil to evaluate safety, tolerability, and efficacy of intranasal Foralumab in a larger number of hospitalized patients with COVID-19.
  • b
    babar
    Buy buy strong buy going to $5 today very huge 🗞
  • m
    m
    Just got proxy to vote. That was easy just look at disgraceful performance and vote accordingly.
  • E
    Enw_Investor
    TLSA is a strong BUY!
  • r
    royee
    Worthless news guys why are you buying this?
  • b
    babar
    What is going on how many good news to go up
  • b
    babar
    Looks time to start dumping always happen after 10.30 am with this stock will close under $1.70
  • S
    Sara
    We need some news soon !!
  • T
    Talibanpicks
    RVPH =CHEAPEST biotech OUT there ,next SAVA for your portfolio which went from $3 to $130

    (RVPH) MCap $56 m--a PHASE 3 company targeting several Blockbuster indications like Alzheimer ,Parkinson ,ADHD and so forth = Undiscovered Goldmine with 10 bagger upside potential guys
    https://assets.wallstreet-online.de/_media/8763/board/20210129182939-screenshot-2021-01-29-form-8-k-tenzing-acquisitio.png

    #+#+#
  • Y
    Yahoo Finance Insights
    Tiziana Life Sciences is up 8.93% to 1.83
  • Y
    Yahoo Finance Insights
    Tiziana Life Sciences is down 8.91% to 1.59
  • Y
    Yahoo Finance Insights
    Tiziana Life Sciences is down 9.46% to 1.88
  • M
    Me
    So the CEO pays himself 13.5mill a year yet holds none of his own stocks. Hardly any institutional owners. No revenue. What is there to like here ..!?
  • Y
    Yahoo Finance Insights
    Tiziana Life Sciences is up 8.76% to 2.11